
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Teva Pharmaceutical Industries Ltd. has received final FDA approval to market a generic formulation of finasteride tablets, 5 mg.
Teva Pharmaceutical Industries Ltd. has received final FDA approval to market a generic formulation of finasteride tablets, 5 mg. Finasteride is indicated for treatment of symptomatic BPH. Shipments will begin immediately.
As the first company to file the application with a paragraph IV certification for this product, Teva said it has been awarded marketing exclusivity for its formulation through mid-December 2006.





